Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection

被引:0
作者
Masaaki Murakawa
Shinnosuke Kawahara
Daishi Takahashi
Yuto Kamioka
Naoto Yamamoto
Satoshi Kobayashi
Makoto Ueno
Manabu Morimoto
Sho Sawazaki
Hiroshi Tamagawa
Takashi Ohshima
Norio Yukawa
Yasushi Rino
Soichiro Morinaga
机构
[1] Kanagawa Cancer Center,Department of Gastrointestinal Surgery
[2] Kanagawa Cancer Center,Department of Gastroenterology
[3] Yokohama City University School of Medicine,Department of Surgery
来源
World Journal of Surgical Oncology | / 21卷
关键词
Pancreatic ductal adenocarcinoma; Early recurrence; Risk factors; Neoadjuvant therapy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 175 条
[1]  
Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249
[2]  
Ferlay J(2021)Pancreatic cancer: a review JAMA 326 851-862
[3]  
Siegel RL(2020)Pancreatic cancer Lancet 395 2008-2020
[4]  
Laversanne M(2017)Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial Lancet 389 1011-1024
[5]  
Soerjomataram I(2018)FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer N Engl J Med 379 2395-2406
[6]  
Jemal A(2016)Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) The Lancet 388 248-257
[7]  
Bray F(2007)Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA 297 267-277
[8]  
Park W(2010)Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial JAMA 304 1073-1081
[9]  
Chawla A(2019)Recent eUpdates to the ESMO Clinical Practice Guidelines on hepatocellular carcinoma, cancer of the pancreas, soft tissue and visceral sarcomas, cancer of the prostate and gastric cancer Ann Oncol 30 1395-1397
[10]  
O'Reilly EM(2021)Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology J Natl Compr Canc Netw 19 439-457